Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects With Advanced Parkinson's Disease.

Trial Profile

Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects With Advanced Parkinson's Disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2012

At a glance

  • Drugs NLX P101 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Neurologix
  • Most Recent Events

    • 21 Feb 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 Aug 2011 Several patients have been treated with NLX P101 in the open-label part of the trial.
    • 08 Jun 2011 The results from this study were presented to the National Institutes of Health Recombinant DNA Advisory Committee.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top